Predictive blood system with use of methylation signatures for outcome of hepatocellular carcinoma
Project/Area Number |
24592002
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Digestive surgery
|
Research Institution | Yamaguchi University |
Principal Investigator |
IIZUKA Norio 山口大学, 医学部附属病院, 准教授 (80332807)
|
Project Period (FY) |
2012-04-01 – 2015-03-31
|
Project Status |
Completed (Fiscal Year 2014)
|
Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2014: ¥260,000 (Direct Cost: ¥200,000、Indirect Cost: ¥60,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
|
Keywords | 肝癌 / メチル化 / 血清DNA |
Outline of Final Research Achievements |
The purpose of this study is to develop a minimally invasive predictive blood test with use of methylation signature specific to hepatocellular carcinoma (HCC) for outcome of HCC. Out of 20 methylation genes with CpG islands in the promoter and exon 1 regions, we identified 6 genes, such as CFTR, RASF1A, and BASP, linked to metastatic potentials of HCC. We found that 6-genes predictive scoring system had sensitivity and specificity of 56% and 68% in predicting outcome of HCC in the training set. The system worked well (sensitivity and specificity of more than 60%) in the test set. Moreover, we found that number of genes positive for methylation is critical to understanding of metastatic potentials of HCC. We reported the relevant results in the form of 9 papers (2 Anticancer Res., 4 Int J Oncol ., 1J Transl Med, 1 Oncol Rep, and 1 Frontiers in Pahrmacology) and read 3 papers at academic meetings. We obtained a patent linked to methodology for the system.
|
Report
(4 results)
Research Products
(10 results)
-
[Journal Article] Preoperative serum methylation signature as prognostic tool after curative hepatectomy in patients with hepatocellular carcinoma2015
Author(s)
Kanekiyo S, Iizuka N, Tsunedomi R, Tokumitsu Y, Hashimoto N, Tokuhisa Y, Maeda Y, Iida M, Sakamoto K, Tamesa T, Fujita Y, Yoshino S, Hazama S, Hamamoto Y, Oka M.
-
Journal Title
Anticancer Res.
Volume: 35
Pages: 997-1007
Related Report
Peer Reviewed
-
-
[Journal Article] Predictive biomarkers for the outcome of vaccination of five therapeutic epitope peptides for colorectal cancer.2014
Author(s)
Hazama S, Takenouchi H, Tsunedomi R, Iida M, Suzuki N, Iizuka N, Inoue Y, Sakamoto K, Nakao M, Shindo Y, Kanekiyo S, Tokumitsu Y, Yoshimura K, Maeda N, Maeda K, Maeda Y, Matsui H, Yoshino S, Nakamura Y, Fujita Y, Hamamoto Y, Okamoto M, Fujita T, Kawakami Y, Oka M.
-
Journal Title
Anticancer Res.
Volume: 34
Pages: 4201-4205
Related Report
Peer Reviewed
-
-
-
-
-
-
-